195611-82-6

Usage

Uses

Used in Pharmaceutical Industry:
GW7604 is used as a therapeutic agent for the treatment of metabolic disorders such as type 2 diabetes and dyslipidemia, leveraging its ability to improve insulin sensitivity and lipid metabolism.
Used in Anti-inflammatory Applications:
GW7604 is utilized as an anti-inflammatory agent, capitalizing on its capacity to reduce inflammation which is a common factor in many diseases.
Used in Anti-atherogenic Applications:
GW7604 is employed as an anti-atherogenic agent, helping to combat the development of atherosclerosis by potentially influencing the processes that lead to plaque formation in arteries.
Used in Anti-diabetic Applications:
GW7604 is used as an anti-diabetic medication, enhancing insulin sensitivity and aiding in the management of blood sugar levels in patients with diabetes.
Used in Oncology:
GW7604 is used as a potential therapeutic agent in cancer treatment, due to its demonstrated ability to inhibit the proliferation and metastasis of various cancer cell lines by activating PPARδ.
Used in Drug Development Research:
GW7604 serves as a valuable compound in pharmaceutical research for the development of new drugs targeting PPARδ, potentially leading to novel treatments for a variety of diseases.

Upstream product

• 78423-10-6 1-(4-methoxyphenyl)-2-phenylbutan-1-one 
• 100-66-3 methoxybenzene 
• 36854-57-6 2-Phenylbutyryl chloride 
• 1371574-24-1 (E)-3-{4-[(E/Z)-1-(4-methoxyphenyl)-2-phenylbut-1-enyl]phenyl}acrylic acid 

Relevant academic research and scientific papers

Development of bivalent triarylalkene- and cyclofenil-derived dual estrogen receptor antagonists and downregulators

Up to 80% of mammary carcinoma initially exhibit estrogen-dependent growth, which can be treated by aromatase inhibitors or SERMs/SERDs. To increase the options after failure of the hormonal therapy with these drugs, the search for alternatives with a dif

Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity

Estrogen receptor α (ERα) is an important target for the design of drugs such as tamoxifen (2a) and fulvestrant (5). Three series of ER-ligands based on the benzoxepin scaffold structure were synthesized: series I containing an acrylic acid, series II with an acrylamide, and series III with a saturated carboxylic acid substituent. These compounds were shown to be high affinity ligands for the ER with nanomolar IC50 binding values. Series I acrylic acid ligands were generally ERα selective. In particular, compound 13e featuring a phenylpenta-2,4-dienoic acid substituent was shown to be antiproliferative and downregulated ERα and ERβ expression in MCF-7 breast cancer cells. Interestingly, from series III, the phenoxybutyric acid derivative compound 22 was not antiproliferative and selectively downregulated ERβ. A docking study of the benzoxepin ligands was undertaken. Compound 13e is a promising lead for development as a clinically relevant SERD, while compound 22 will be a useful experimental probe for helping to elucidate the role of ERβ in cancer cells.